Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE) for its drug candidate SHR-1918. This in-house developed monoclonal antibody (mAb) targeting angiopoietin-like protein 3 (ANGPTL3) is intended for the treatment of homozygous familial hypercholesterolemia (HoFH).
SHR-1918 operates by reducing serum levels of triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C), achieved by inhibiting the activity of ANGPTL3. A comparable drug in the global market is Regeneron’s Evkeeza (evinacumab), which targets the same mechanism.
HoFH is a rare and severe genetic disorder characterized by defects or deficiencies in the low-density lipoprotein cholesterol receptor (LDLR), leading to an accumulation of LDL-C in the blood and consequently increasing the risk of heart disease and stroke. – Flcube.com
